Dermatology Education Foundation

Big news! Bimzelx® (bimekizumab) is FDA-approved for moderate-to-severe hidradenitis suppurativa, with strong results in Phase 3 trials. Learn more on the DEF blog and join our FREE Virtual Bootcamp Dec. 1!

A new whole-cell vaccine cleared infections faster and reduced bacterial burdens in mice, marking a big step forward in an 80-year quest. 🌍 With 40M+ affected worldwide, this could be a game-changer! 📖 Read more on the DEF blog. #ChlamydiaVaccine #Chlamydia

New research links HSV-1 to potential neurodegenerative impacts like Alzheimer’s. It maps HSV-1's path through the central nervous system, affecting regions for sleep, movement, and mood, with microglia inflammation as a key factor.

New data shows a 2.8-fold rise in cutaneous malignant melanoma (CMM) among elderly Americans. A separate study on Marjolin’s ulcer (MU) reveals changes in keratinocytes that promote tumor growth. Insights could aid future treatments. #skincancer #melanoma

New data shows lebrikizumab (Ebglyss) benefits moderate-to-severe eczema patients previously treated with dupilumab. At 16 weeks, 57% reached EASI-75; results improved at 24 weeks, with notable itch relief. Minimal discontinuations reported.

Register Here ➡️ us02web.zoom.us/webinar/regist…

Join us tomorrow, Nov 5 at 8 PM, for a free CME webinar on atopic dermatitis treatment updates. Featuring Jonathan Silverberg, MD, PhD, MPH, and Sandri Johnson, MSN, FNP-BC, DCNP.

Join us at the next DEF Biologic & Small Molecule Bootcamp! Network, learn the latest data, and connect with industry peers. Thanks to our sponsors for their support! 🗓️ Saturday, November 9, 2024 📍 Hyatt Regency Huntington Beach

Join us tonight from 8-9 PM ET 👩‍💻 Olumiant: 3 Year Data for Adults with Severe Alopecia Areata. Register now! dermnppa.org/events/olumian…

#psoriasis is more than a skin condition—it’s a complex inflammatory disease. At DEF Bootcamp, Sandri Johnson, MSN, FNP-BC, shared how holistic, patient-centered care improves outcomes. Learn more at the DEF Biologic & Small Molecule NP/PA CME Bootcamp on Nov 9.

The FDA has accepted the sNDA for Zoryve (roflumilast) foam 0.3% for scalp and body psoriasis, with promising data from the ARRECTOR trial showing rapid relief of itch and clearance of lesions. Stay tuned for updates! #Psoriasis

Bimzelx from UCB is now FDA approved for psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), and ankylosing spondylitis (AS). A big win for patients needing new treatment options! #PsA #Bimzelx #FDAApproval

The FDA is reviewing LEO Pharma’s delgocitinib cream for potential approval! Learn about the results from their DELTA clinical trials and how this topical pan-JAK inhibitor may provide a new option for moderate to severe CHE.

What we can do together is magical.✨ National PA Week is in full swing, and we’re giving a big shoutout to all the PAs making an impact in dermatology! 💙 #PAWeek #DermPAs

National PA Week is almost here! 🎉 From Oct 6-12, we’re celebrating PAs across all specialties, especially those making a difference in dermatology. 💙 #PAWeek #DermPA #PAsGoBeyond

@nationaleczema 6/6 By centering patient experiences, the NEA is working to close the gap between clinical definitions and real-world experiences of eczema flares. For more details visit the DEF Blog dermnppa.org/what-is-an-ecz…

@nationaleczema 5/6 These insights are helping refine our understanding of eczema flares, so they more accurately reflect the real-life challenges faced by those living with the condition. #EczemaCare

What exactly is an eczema flare? 🤔 1/6 The National Eczema Association (@nationaleczema) is redefining what it means to experience an eczema flare by listening to those who live with it every day. 💬 #EczemaFlare #Eczema